Biostem Technologies (BSEM) Corporate presentation summary

Mission and vision

• Focused on delivering advanced wound healing technologies to improve patient outcomes.

• Committed to innovation in regenerative medicine, particularly perinatal tissue allografts.

Market opportunity and need

• Addresses a $23B US soft tissue allograft market across orthopedics, wound care, spine, urology, and women’s health.

• Regenerative medicine reduces complications and accelerates healing, with significant economic and patient impact.

Technology and product portfolio

• Proprietary platforms: BioRetain, CryoTek, and SteriTek, preserving natural tissue properties.

• Six perinatal-derived allograft brands, including Neox and Clarix, with multiple product formats for surgical and wound care.

• Over 90 clinical publications support product efficacy.